An FDA-approved arthritis drug slowed aggressive kidney cancer in lab tests

by Adrienne Erin

Researchers have traced a possible path from a gene-regulating protein called SMARCD1 to the shape of mitochondria in aggressive kidney cancer, and tested an FDA-approved arthritis drug against it in the lab. The findings are early and mostly preclinical, and the drug is not a cancer treatment, but the work gives scientists a new target. Here is what the study found, how the pieces connect and why it is not ready for patients. (Based on the insights of Physionic)

Key Takeaways

  • Higher levels of the SMARCD1 protein were linked with better outcomes in people with kidney cancer, and knocking it down accelerated cancer growth in three cell lines.
  • Low SMARCD1 appears to allow more expression of the MAF gene, which is linked to worse outcomes, fragmented mitochondria and more invasive-looking cancer cells.
  • Leflunomide, an FDA-approved rheumatoid arthritis drug, reduced tumor growth in high-MAF kidney cancer models, and showed even lower growth alongside tyrosine kinase inhibitors and immunotherapy.
  • The work is mostly preclinical, limited to certain kidney cancers with a low-SMARCD1 profile, and needs clinical trials before anyone knows if it helps patients.
  • Leflunomide has serious risks of its own and should never be used for cancer without specialist supervision.

Why Mitochondria And Cancer Keep Coming Up

The link between cancer, metabolism and mitochondria, the powerhouses of the cell, goes back about a century. There has even been debate about whether cancer begins as a genetic disease or a mitochondrial one. A new study suggests the two may be connected: it traces a path from a gene-regulating protein to the shape of mitochondria, and then to a possible way of interfering with aggressive cancer using a drug that is already approved for something else. Before the details, an important point: nearly all of this is laboratory research, and it is not a treatment available to patients.

SMARCD1: A Protein Linked To Better Outcomes

Cells contain a large complex of proteins called SWI/SNF, and one of its members is called SMARCD1. When researchers sorted people with kidney cancer by how much of this protein their tumors produced and followed them over time, those with higher SMARCD1 had better outcomes and less progression. SMARCD1 was also found to be unusually low in more aggressive, invasive cancers. That is an association, and it does not prove cause and effect, since thousands of proteins could follow a similar pattern.

To test it more directly, researchers switched off (knocked down) SMARCD1 in three kidney cancer cell lines. In all three, cancer cell growth accelerated compared with cells where SMARCD1 was intact. That suggests the protein helps hold cancer in check, at least in these cell models.

How The Gene Packaging Connects To MAF

SMARCD1 is part of a machine that interacts with nucleosomes, which are packages of eight histone proteins with DNA wrapped around them. By shifting nucleosomes closer together or farther apart, it can close genes or open them so they can be read and turned into proteins. After a series of experiments, researchers identified a gene called MAF that showed a strong signal.

In people with the same cancer, higher MAF expression was linked to much worse outcomes, the reverse of SMARCD1. MAF was also highly expressed in cancerous tissue, and knocking it down reduced cancer cell growth in the lab. In short, low SMARCD1 appears to allow more MAF, and more MAF appears to go with more aggressive cancer.

What MAF May Do To Mitochondria

When MAF is present in cells, the mitochondria fragment and shrink. Microscopy images showed long, tube-like mitochondria in non-cancerous cells, smaller and less tubular mitochondria when MAF was switched on, and recovery of the elongated shape when MAF was silenced. Cancer cells with high MAF also grew many aggressive-looking protrusions called invadopodia, a visual sign of cells seeking to invade surrounding tissue as in metastasis. When MAF was knocked down, the cells looked much tamer. These observations tie the genetic story directly to mitochondrial changes.

An Old Arthritis Drug Enters The Picture

Because of these mitochondrial effects, researchers tested leflunomide, an FDA-approved drug used for rheumatoid arthritis, against kidney cancers with high MAF. In laboratory models, the drug on its own reduced tumor growth. When it was combined with other cancer treatments, including tyrosine kinase inhibitors and immunotherapy, tumor growth was lower still, and in the combination with the strongest effect the tumors might even have been shrinking. This suggests the drug could be effective at keeping an aggressive cancer from behaving aggressively, especially alongside other therapies, if the results translate to people.

Why This Is Not Ready For Patients

  • Mostly preclinical. Beyond the human outcome associations, the findings come from cell and laboratory experiments, which are compelling but not yet translatable.
  • No clinical trials yet. Trials repurposing the drug would be needed to assess whether it works in patients and at what dose.
  • Safety is partly known. The drug’s prior approval gives an idea of its safety profile in arthritis, which is encouraging, but it is a prescription medicine with serious risks of its own, including liver problems and harm in pregnancy, so it should never be used for cancer without specialist supervision.
  • Only certain kidney cancers. The cancers studied were clear cell, papillary and chromophobe renal cell carcinoma, and they had to fit the low-SMARCD1 profile to be affected.

What This Means For You

This is a notable discovery that bridges genetics and mitochondria, and it gives scientists a specific protein and pathway to investigate. For people with kidney cancer, the practical step is to discuss treatment options with an oncologist and ask about clinical trials. Nobody should start or take leflunomide for cancer on their own.

Frequently Asked Questions

Can an arthritis drug stop kidney cancer?

Not as far as anyone knows yet. In laboratory models of kidney cancers with high MAF, leflunomide reduced tumor growth, especially combined with other treatments, but this has not been tested in patients. Clinical trials would be needed to learn whether it works and at what dose.

What is SMARCD1?

It is a protein in the SWI/SNF complex, which helps tighten or loosen the packaging around DNA so genes can be read. Higher SMARCD1 was associated with better cancer outcomes, and switching it off accelerated cancer growth in three kidney cancer cell lines.

What does MAF have to do with mitochondria?

MAF is a gene that seems to be switched on more when SMARCD1 is low. When MAF was present, mitochondria fragmented and shrank and cancer cells looked more invasive, and when MAF was silenced, mitochondria recovered their elongated shape and cells looked tamer.

Should people with kidney cancer ask about leflunomide?

It is reasonable to ask an oncologist about clinical trials and emerging research, but leflunomide is a prescription drug with serious risks, including liver problems and harm in pregnancy, and it should not be started for cancer without specialist guidance.

Questions To Ask Your Oncology Team

  • ☐ Ask which type of kidney cancer you have and what treatments are standard
  • ☐ Ask whether any clinical trials are open to you
  • ☐ Ask whether tumor testing could be relevant to emerging research
  • ☐ Never start a repurposed drug on your own
  • ☐ Report new symptoms or side effects to your care team promptly

This article is for general educational purposes and is not medical advice. The research described is mostly laboratory (preclinical) work in kidney cancer cells and models, and it has not been tested in clinical trials. Leflunomide is a prescription medicine with serious risks and should not be used for cancer without specialist supervision. Talk to your oncologist about treatment options and clinical trials.

Adrienne Erin

Adrienne holds a Bachelor of Science in Kinesiology, where she developed a strong foundation in exercise physiology and human nutrition. Before joining DailyHealthPost, she spent several years writing about health and wellness topics, translating nutrition and fitness research into practical guidance for everyday readers.

Advertisement